Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity

Blood

Volumn 99, Issue 9, 2002, Pages 3179-3187

  Bollard, Catherine M ^a,b   Rössig, Claudia ^a,b   Julia Calonge, M ^a,b   Helen Huls, M ^a,b   Wagner, Hans Joachim ^a,b   Massague, Joan ^a,b   Brenner, Malcolm K ^a,b   Heslop, Helen E ^a,b   Rooney, Cliona M ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GREEN FLUORESCENT PROTEIN; PERFORIN; SMAD PROTEIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENETIC TRANSDUCTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LONG TERM CARE; MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TUMOR IMMUNITY;

EID: 0036566184     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.9.3179     Document Type: Article

References (63)

1. Deficient cellular immunity-finding and fixing the defects
2. Antigen-specific tumor vaccine. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy
3. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
4. The host-tumor immune conflict: From immunosuppression to resistance and destruction
5. The transforming growth factor-beta family
6. Transforming growth factor beta in tissue fibrosis
7. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
8. The transforming growth factor-betas. A new family of immunoregulatory molecules
9. Differential effect of transforming growth factor beta on the synthesis of Th1-and Th2-like lymphokines by human T lymphocytes
10. Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine
11. Transforming growth factor beta regulates differentiation and proliferation of human neuroblastoma
12. Immune escape mechanisms in Hodgkin's disease
13. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type Il receptors
14. TGF beta signals through a heteromeric protein kinase receptor complex
15. Mechanism of activation of the TGF-beta receptor
16. Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region
17. Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex
18. Distinct oligomeric states of SMAD proteins in the transforming growth factor-beta pathway
19. TGF-beta signal transduction
20. Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1)
21. Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin Dl-cdk4 association in human mammary epithelial cells
22. Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor
23. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha
24. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-beta
25. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma
26. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease
27. + Hodgkin disease
28. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus
29. The structure of an antigenic determinant in a protein
30. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells
31. In vitro transformation of human B-cell follicular lymphoma cells by Epstein-Barr virus
32. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts
33. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
34. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
35. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras
36. Advances in quantitative PCR technology: 5′ nuclease assays
37. Effects of TGF-beta on the immune system: Implications for cancer immunotherapy
38. Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA
39. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
40. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs
41. + cytotoxic T-cell responses during chronic viral infection
42. Going mad with Smads
43. Failure of TGF beta1 and IL-12 to regulate human FasL and mTNF alloreactive cytotoxic T-cell pathways
44. Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-beta-treated alloreactive T cells that do not induce graft-versus-host disease
45. TGF-beta does not inhibit IL-12- and IL-2-induced activation of Janus kinases and STATs
46. Transforming growth factor-beta1 suppresses interleukin-15-mediated interferon-gamma production in human T lymphocytes
47. + Th1/Th2 T cells
48. Downregulation of interleukin-12 (IL-12) responsiveness in human T cells by transforming growth factor-beta: Relationship with IL-12 signaling
49. IFN-beta and TGF-beta differentially regulate IL-12 activity in human peripheral blood mononuclear cells
50. + T lymphocytes. Inhibition by transforming growth factor-beta
51. Cytokines: Principles and prospects
52. TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes
53. Mechanism of inhibition of eosinophil activation by transforming growth factor-beta. Inhibition of Lyn, MAP, Jak2 kinases and STAT1 nuclear factor
54. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
55. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system
56. Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles
57. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes
58. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
59. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor
60. Antigen-specific development of primary and memory T cells in vivo
61. Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selection on T cells during the virgin to memory cell transition
62. Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc
63. - pre-T cell subset